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The infection of cynomolgus monkeys with an attenuated simian immunodeficiency virus (SIV) (C8) carrying a deletion in
the nef gene results in a persistent infection associated with an extremely low viral burden in peripheral blood mononuclear
cells. The aim of this study was to determine (1) the breadth of the protection after repeated challenges of monkeys with SIV
homologous strains of different pathogenicity, (2) the genotypic stability of the live virus vaccine, (3) whether the protection
might depend on cellular resistance to superinfection, and (4) whether immunogenic stimuli such as recall antigens could
reactivate the replication of the C8 virus. To address these goals, the monkeys were challenged at 40 weeks after C8
infection with 50 MID50 of cloned SIVmac251, BK28 grown on macaque cells. They were protected as indicated by several
criteria, including virus isolation, anamnestic serological responses, and viral diagnostic PCR. At 92 weeks after the first
challenge, unfractionated peripheral blood mononuclear cells from protected monkeys were susceptible to the in vitro
infection with SIVmac32H, spl. At 143 weeks after C8 infection, the four protected monkeys were rechallenged with 50 MID50
of the pathogenic SIVmac32H, spl grown on macaque cells. Once again, they were protected. The C8 virus remained
genotypically stable, and depletion of CD41 cells was not observed during ;3 years of follow-up. In contrast, it was found
that the infection with SIVmac32H, spl induced CD4
1 cell depletion in three of three control monkeys. Of importance, stimulation
with tetanus toxoid, although capable of inducing specific humoral and T cell proliferative responses, failed to induce a
detectable reactivation of C8 virus. © 1999 Academic PressKey Words: live virus vaccine, simian immunodeficiency virus, tetanus toxoid.
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In the past decade, several vaccination strategies
gainst the human immunodeficiency virus (HIV) have
een evaluated in the simian immunodeficiency virus
SIV) macaque model. Whole inactivated (Almond et al.,
995; Dormont et al., 1995; Stahl-Hennig et al., 1996a; Titti
t al., 1993) or subunit (Hu et al., 1992; Israel et al., 1994;
ehner et al., 1996) SIV vaccines have been shown to be
artially effective in preventing infection or in reducing
iral burden in monkeys challenged with low doses of
ell-free or cell-associated homologous or heterologous
iruses. A common characteristic of all these vaccine
rials in macaques was the capability of inducing hu-
oral and cellular immune responses, which, however,
ere not always sufficient in obtaining a complete pro-
ection or a significant reduction in viral load (Giavedoni
t al., 1993; Hulskotte et al., 1995; Mills et al., 1993).
At the present, the vaccination of macaques with live
ttenuated SIV strains yielded the most consistent pro-
ection data in the SIV macaque model (Almond et al.,
1 To whom reprint requests should be addressed. Fax: 39-06-
a9387184. E-mail: titti@virus1.net.iss.it.
291995; Cranage et al., 1997; Daniel et al., 1992; Norley et
l., 1996; Stahl-Hennig et al., 1996a; Titti et al., 1997;
yand et al., 1996). More recently, chimeric SIV-contain-
ng portion of HIV regions (SHIV) has also been used as
vaccine (Igarashi et al., 1997; Letvin et al., 1995) or as
hallenge virus (Bogers et al., 1995; Shibata et al., 1997).
espite the proved efficacy of live attenuated SIV vac-
ines in monkeys, there remain safety concerns regard-
ng the use of a similar approach in humans. Among the
afety issues is the possible reaction that may occur in
atients vaccinated with an attenuated HIV after vacci-
ation against other infectious agents or after exposure
o foreign antigens. In fact, a major characteristic of the
nfection with an attenuated virus is the establishment of
persistent but attenuated infection. It is well known
rom in vitro studies that cellular activation and produc-
ion of inflammatory cytokines can reactivate latent vi-
uses (Fauci, 1993; Goletti et al., 1998) and/or rescue
efective proviruses (Barillari et al., 1992). In addition,
ther studies, in both animals and humans, have re-
orted evidence of the association between immune
ctivation or dysregulation and clinical course of the
isease in HIV-infected patients, SIV-infected monkeys,
nd Visna virus-infected sheep (Folks et al., 1997; Fultz et
0042-6822/99 $30.00
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292 SERNICOLA ET AL.l., 1992; O’Brien et al., 1995; Ostrowsky et al., 1997;
tanley et al., 1996).
To examine the protection elicited by a naturally oc-
urring variant of SIVmac251, 32H (C8) carrying an in-frame
2-bp deletion in the nef gene (Rud et al., 1992, 1994),
ynomolgus macaques have been infected with the C8
ive attenuated virus to (1) evaluate its capability of es-
ablishing a protective status against subsequent chal-
enges with SIV strains differing in their pathogenic po-
ential, (2) verify the genotypic stability of the C8 virus
efore and after viral challenges, (3) test the susceptibil-
ty of peripheral blood mononuclear cells (PBMCs) from
rotected monkeys to the in vitro infection with SIV, with
he goal of determining whether a phenomenon of cel-
ular resistance to superinfection could occur, and (4)
tudy the effect of immune stimulation with a recall
ntigen on reactivation of the vaccine virus.
In this study, we demonstrate that vaccination with live
ttenuated virus elicits a strong protective status, as
emonstrated by the protection against repeated chal-
enges with homologous SIV strains of increasing patho-
enicity, which lasts ;3 years. This effect does not seem
o be related to a cellular resistance to superinfection. Of
mportance, we found that the immune stimulation with a
ommon recall antigen [tetanus toxoid (TT)] does not
pparently reactivate the replication of the vaccine virus.
RESULTS
nfection of cynomolgus monkeys with the nef-deleted
8 virus results in protection against the first
hallenge
The outcome of the infection of cynomolgus monkeys
ith the C8 virus has been reported (Titti et al., 1997).
riefly, each of the four C8-infected animals serocon-
erted at the fourth week after infection and anti-SIV
ntibody titers progressively increased (Fig. 1A). C8 virus
stablished a persistent infection characterized by a very
ow viral load (data not shown). The C8-vaccinated mon-
eys were protected from the first challenge with 50
ID50 of SIVmac, BK28 that was inoculated 40 weeks after
he primary infection, as indicated by the failure to isolate
he challenge virus from PBMCs (Table 1). However, the
8 virus, although no longer isolated from PBMCs, was
solated from lymph node cells of two of three vaccinated
nd protected monkeys. In any case, SIV provirus show-
ng the genotype of the vaccine virus was detectable in
amples of all monkeys by nested DNA PCR. In addition,
either histological modifications of lymph nodes nor
D41 cell depletion was observed among the same
onkeys. In contrast, SIVmac, BK28 was isolated from PBMCs
f all monkeys and from lymph node cells of three of four
ontrol monkeys. The infection with SIVmac, BK28 induced
n control monkeys a CD41 cell depletion, which was
ore evident in monkeys 28 and 91 at 62 weeks post-hallenge (p.c.). In addition, microhemorrhagic areas and 1nfiltration of lymphocytes to germinal centers were ob-
erved at 28 weeks p.c. in three of four control monkeys.
usceptibility of PBMCs from C8-vaccinated and
rotected monkeys to in vitro infection with SIV
To determine whether the protection in C8-vaccinated
onkeys might depend on a cellular resistance to su-
erinfection, SIVmac32H, spl was used to infect in vitro
nfractionated PBMCs (multiplicity of infection, 1 TCID50/
ell) from C8-vaccinated and two naive monkeys. Before
he in vitro infection, the C8 provirus was undetectable by
single-round PCR in PBMCs of all vaccinated monkeys
data not shown) and was still undetectable after PHA
timulation of the same PBMCs (Fig. 2B). In contrast,
fter in vitro infection, SIV provirus was detectable by the
ame method in PHA-stimulated PBMCs of both vacci-
ated and naive monkeys. In particular, because the
2-bp deletion in the nef region of the C8 virus eliminates
ne of the two RsaI recognition sites, a nested-PCR
iagnostic assay was used to distinguish between the
8 and the full-length nef of SIVmac32H, spl proviruses.
pecifically, after in vitro infection, full-length nef DNA
ould be detected in samples of both vaccinated and
ontrol monkeys (Fig. 2C). Although there were individual
ariations, PBMCs of vaccinated monkeys were produc-
ively infected, as indicated by the presence of p27gag
ntigen in the culture supernatants at levels comparable
o those found in the supernatants of PBMCs from con-
rol monkeys (Fig. 2A).
he second challenge of C8-vaccinated monkeys with
ild-type SIV results in protection from infection
Based on the previous results and to verify the breadth
f the protection, the four vaccinated and protected mon-
eys along with three naive monkeys were rechallenged
ith 50 MID50 of the same strain of wild-type SIVmac32H, spl
sed for in vitro infection at week 103 after the first
hallenge (143 weeks from the original C8 infection).
ontrol monkeys seroconverted (Fig. 1B) and a peak of
27gag plasma antigen was observed at 2 weeks postin-
ection (p.i.) (data not shown) paralleled by an increase of
he SIV proviral copies at 2 and 8 weeks p.i. (Table 2).
fter the rechallenge, a moderate increase of anti-SIV
ntibody titers was observed (Fig. 1A) in vaccinated
onkeys that, however, remained virus-isolation nega-
ive (Table 2). The level of plasma p27gag antigen was at
o time detectable (,50 pg/ml) by commercial p27gag
ntigen capture assay (data not shown). At the time of
he second challenge, the cell-associated viral load was
ndetectable in two of four monkeys (7 and 46133),
hereas it was ,10 SIV proviral copies/mg of DNA in
onkeys 09 and 33. A moderate increase in the SIV
roviral copies was detectable at 2 weeks p.c. in three of
our monkeys, being more evident in monkey 09, and, at
3 weeks p.c., in monkey 46133. However, the C8 ge-
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293IMMUNE STIMULATION DOES NOT REACTIVATE ATTENUATED SIVome maintained its original deletion (amino acids 144–
47) because no sequences that correspond to the full-
ength nef DNA genome of the challenge virus were
etected in the PBMCs (at 2 weeks p.c.) by both diag-
ostic PCR assay (Table 2) and sequence analysis of the
ef region (data not shown). Accordingly, full-length nef
NA could be detected in samples of control monkeys.
he percentage of CD41 cells remained rather stable
mong vaccinated monkeys, although some variations
ere observed (Fig. 3). However, a depletion of the CD41
ells was observed among control infected monkeys
uring the period of observation of 31 weeks (Fig. 3). In
articular, disease progression appears to be more pro-
ounced in monkey A91. In fact, the percentage and the
FIG. 1. Anti-SIV antibody titers in plasma of C8-immunized monkeys
nfection (B). Dashed arrows indicate the time at which the tetanus toumber of CD41 cells were 31.75% and 990 cells/mm3, eespectively, at the time of infection and decreased to
.32% and ,10 cells/mm3 at 31 weeks p.i.
timulation with TT does not result in a detectable C8
irus reactivation
To analyze whether immune activation could reacti-
ate the replication of the C8 virus in protected monkeys,
t week 13 after the second challenge, the four vacci-
ated and the three control animals received a booster
mmunization with TT (40 IU/dose/monkey), followed by a
econd booster 3 weeks later. The analysis of the in vitro
roliferation before the first dose of TT (13 weeks p.c.)
evealed that although PBMCs from all monkeys prolif-
and after the challenges (A) and in plasma of naive monkeys after
atment was given (at 13 and 16 weeks after the second challenge).beforerated in response to PHA [stimulatory index (S.I.),
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294 SERNICOLA ET AL.20.0; data not shown)] a specific proliferation to TT was
ndetectable (S.I. # 1.0) (Fig. 4). Six weeks after the first
T booster (3 weeks after the second dose), all C8-
accinated monkeys responded to TT treatment and
howed a specific increase of the proliferative response
S.I. . 2.0; range, 2.93–5.98), and an increase in plasma
gG antibody level to TT (fivefold to ninefold increase
rom the baseline values) (Fig. 4A). Similarly, the specific
.I. was .2 (range, 3.83–7.66) in two fo three control
nfected monkeys with a contemporary increase of an-
i-TT IgG level (from fivefold to eightfold increase from the
aseline values). A poor antibody and proliferative re-
ponse to TT (S.I. 5 1.03 at 13 weeks p.i., S.I. 5 1.42 at 19
eeks p.i.) was observed in the remaining control mon-
ey (monkey A91) (Fig. 4B). The effect of the TT immuni-
ation on the viral load in PBMCs was then evaluated by
emiquantitative DNA PCR. Among the four protected
onkeys, the immune activation induced by TT did not
esult in any detectable increase in the number of SIV
roviral copies (Fig. 4C). In contrast, an increase in the
umber of SIV proviral copies was detectable after the
econd booster with TT in PBMCs of the control unfrac-
ionated monkeys P2 and 2V but not in samples of the
onkey A91, which also showed a weak in vitro prolifer-
tive response (Fig. 4D).
In a parallel study, to evaluate whether SIV infection
ould modify the in vitro proliferative response to anti-
T
Summary of the Responses of C8-Vaccinated (7, 09,
after the First Challen
PBMCs
VCa PCRb VC
8-vaccinated monkey
7 2 1 (C8) N.D.
09 2 1 (C8) 1
33 2 1 (C8) 1
46133 2 1 (C8) 2
aive infected monkey
22 1 1 (BK28) 1
28 1 1 (BK28) 1
91 1 1 (BK28) 1
48126 1h 1 (BK28) 2
a Virus isolation (1, positive; 2, negative) from PMBCs cocultured w
b Differential PCR analysis to discriminate C8 from SIVmac/BK28, perfo
nzyme as described in Materials and Methods.
c Lymphnodal biopsy performed at 28 weeks p.c. Single-cell suspens
onkey cells.
d 1, Presence of microhemorrhagic areas and infiltration of lymphoc
ematoxylin and eosin-stained tissue sections.
e Absolute cell counts at 62 weeks p.c. Numbers in parentheses ind
f Monkey 28 died at 78 weeks p.i.
g Monkey 91 died at 109 weeks p.i.
h At some time points, this monkey was negative for virus isolation.
N.D., not done.en-specific stimulation, we performed an analysis onBMCs from 23 uninfected monkeys of comparable age
nd similarly vaccinated with TT during the first year of
ife. Fifteen of 23 monkeys (65.2%) showed an S.I. of ,2
range, 0.38–1.39), whereas 3 of 23 (13.04%) and 4 of 23
17.3%) monkeys showed an S.I. of .2 (range, 2.38–4.51)
nd .10 (range, 11.43–15.05), respectively. To evaluate
heir capability to respond to a recall antigen, four of
hese monkeys were boosted twice with TT at 3-week
nterval. The proliferative responses that were undetect-
ble in these monkeys (S.I. , 2; range, 0.38–1.39) before
T booster were instead detectable 6 weeks after the
irst TT booster in all monkeys (S.I. . 2; range, 2.83–6.61).
hese data altogether are not in contrast to those ob-
ained from C8-vaccinated and from two of three SIV-
nfected monkeys.
DISCUSSION
We previously reported that monkeys vaccinated with
he C8 virus are protected from the challenge with an
omologous cell-free cloned SIVmac, BK28 (Titti et al.,
997). In the same study, we have observed that the
rotected monkeys had levels of interleukin (IL)-2, inter-
eron-g, and IL-15 mRNAs higher than those of control
onkeys, suggesting that a Th1-like response may be
ne of the correlates of protection along with other virus-
pecific immune responses (Heeney et al., 1997).
46133) and Naive Monkeys (22, 28, 91, and 48126)
SIVmac251/BK28 Virus
Lymph Nodec
CD41
(cells/mm3) ProtectionPCR Histologyd
N.D. N.D. 1570 (1461)e 1
1 (C8) 2 2470 (2600) 1
1 (C8) 2 1220 (869) 1
1 (C8) 2 1180 (986) 1
1 (BK28) 1 1210 (1423)
1 (BK28) 1 650 (1659)f
1 (BK28) 1 650 (1080)g
1 (BK28) 2 1900 (1450)
MX174 human cell line.
n DNA extracted from PBMCs of monkeys by using RSA I restriction
s used for virus isolation and for PCR analysis on DNA extracted from
germinal centers, as observed with histopathological analysis of the
he number of CD41 cells at the day of the first challenge.ABLE 1
33, and
ge with
ith CE
rmed o
ion wa
ytes to
icate tHere we have shown that vaccination with a live at-
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295IMMUNE STIMULATION DOES NOT REACTIVATE ATTENUATED SIVenuated virus establishes and maintains a long-term
3-year) protective status even after a second challenge
ith the homologous SIVmac32H, spl showing a pathogenic
otential higher than that of SIVmac251, BK28 (Naidu et al.,
988), as indicated by the rapid decline in CD41 cells in
ontrol monkeys. During this period, the C8 virus main-
ained its original genotype, as indicated by sequence
nalysis of the nef region in PBMCs of protected mon-
eys. By using the same live attenuated virus, at the
ame dose in rhesus macaques, other groups have re-
orted that in some animals the truncated nef open
eading frame can revert to a wild-type genotype by
estoring or duplicating the nef deleted sequence. Con-
equently, these animals developed an AIDS-like dis-
ase similar to that observed in monkeys inoculated with
athogenic SIV (Dittmer et al., 1995; Whatmore et al.,
995). It remains to be elucidated whether the use of
ifferent species of monkeys (rhesus vs cynomolgus),
ifferent routes of inoculation, or challenge viruses dif-
ering in their pathogenic potential with respect to the
IVmac251 used in our experiment or retroviral recombi-
ations (Wooley et al., 1997) may have any influence on
he reversion to the wild-type genotype.
FIG. 2. Before the second in vivo challenge, PBMCs from the C8-vac
303; A, right) were infected in vitro with SIVmac32H, spl (multiplicity of
easured in the cell-free supernatants of infected PBMCs at 0, 3, 6,
oninfected (2) or SIV-infected (1) PBMCs, DNA PCR was performed
iscriminate the C8 virus from superinfecting SIVmac32H, spl, a nested P
SA I digestion as described in Materials and Methods (C). (B and C,In a previous study (Titti et al., 1993), we demonstrated shat a long immunization schedule (;2 years) with a
hole inactivated SIV vaccine was insufficient to achieve
rotection in cynomolgus monkeys. Thus from these as
ell as from data by others (Norley et al., 1996; Wyand et
l., 1996), it seems that the capability of the live attenu-
ted virus to continuously replicate without induction of a
evere immune defect (CD41 cell depletion) has a cen-
ral role to mount and maintain a fully protective status.
lthough the vaccination with a live attenuated SIV rep-
esents the most successful result in the past and cur-
ent vaccine approaches, the mechanisms underlying
he protective effect of vaccination are not yet fully un-
erstood. As described for murine leukemia viruses
Mitchell et al., 1992) and for HIV (Hart et al., 1990;
addeo et al., 1993), a nonimmune mechanism such as
iral interference to superinfection may play an important
ole in the establishment of the protection from challeng-
ng viruses. This hypothesis is not sustained by the
eport that monkeys vaccinated with live attenuated
IV-2 become superinfected when challenged with het-
rologous uncloned SIVsm, even if they were still pro-
ected from the clinical signs of the disease for a con-
iderable period of time (Putkonen et al., 1995). Here we
(7, 09, 33, and 46133; A, left) and from two naive monkeys (54219 and
on, 1 TCID50/cell). The p27
gag SIV protein (ng protein/106 cells) was
13 days after infection. To evaluate the presence of SIV provirus in
ng a set of primers amplifying the gag region (496 bp) of SIV (B). To
ay was performed. The PCR products were analyzed before and after
onkey codes are reported.cinated
infecti
10, and
by usi
CR asshow that unfractionated PBMCs from vaccinated and
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296 SERNICOLA ET AL.rotected monkeys are susceptible to in vitro infection
ith SIV, similar to those from uninfected monkeys. Our
ata support the hypothesis that the protection observed
ith attenuated SIV is based not on the competition for
vailable target cells but rather on the ability of the live
ttenuated virus to induce a long-lasting protective im-
une response or responses adequate to prevent or to
ontrol the replication of the challenge virus. In fact,
trong immune responses have been reported to be
ssociated with protection established after vaccination
ith different attenuated viruses in macaques (Clements
t al., 1995; Cranage et al., 1997; Gauduin et al., 1998;
ohnson et al., 1997; Lohman et al., 1994; Xu et al., 1997),
s well as in Friend leukemia murine model (Dittmer et
l., 1998).
As mentioned above, the live attenuated virus still repre-
ents the most successful vaccine approach to prevent SIV
nfection. Nevertheless, apart from the contrasting evidence
f its pathogenic potential in macaques (Baba et al., 1995;
esrosiers et al., 1998; Wyand et al., 1997), the effects of
ther factors on the evolution of the attenuated infection
ave not been fully elucidated. Activation of the immune
ystem is associated with an increased replication of HIV in
nfected patients. We have previously shown that the treat-
ent of SIV-infected macaques with inactivated whole SIV
r with nonspecific antigens, although leading to an in-
rease in the number of circulating T cells, could induce an
ncrease of the cell-associated viral load, probably predis-
osing the monkeys to an accelerated clinical course of the
nfection (Titti et al., 1996). However, in this study, the acti-
ation of the immune system induced by TT did not cause
T
Virus Reisolation and Cell-Associated Viral Load in PBMCs of
Cynomolgus Monkeys after the Second
Time
(weeks p.i.)a
7 09
VCb VLc VC VL VC
econd challenge 143 2 ,1 2 2 2
144 2 N.D. 2 N.D. 2
145 2 9.6 (C8)d 2 96 (C8) 2
147 2 N.D. 2 N.D. 2
151 2 ,1 2 10 2
156 2 ,1 2 52 2
159 2 ,1 2 3 2
162 2 ,1 2 ,1 2
174 2 ,1 2 3 2
a Weeks after C8 infection.
b Virus isolation (1, positive; 2, negative) from PBMCs cocultured w
c Cell-associated viral load (number of SIV proviral copies/mg of DNA
nd Methods.
d Qualitative DNA PCR analysis by using primers amplifying a 356-b
he virus (C8 or SIVmac32H/spl), as indicated by diagnostic nested PCR a
restriction enzyme as described in Materials and Methods.
N.D., not done.detectable reactivation of the C8 virus in vaccinated and (rotected monkeys. Specifically, TT activated the immune
ystem by inducing an increase of the in vitro proliferative
esponse and of plasma IgG and, at the same time, induced
n increase of SIV proviral copies in two of three control
onkeys. In monkey A91, as already observed in HIV-
nfected patients (Oprail et al., 1991), the severity of the
mmune deficit correlated with the absence of TT response
nd with detectable variations of the number of SIV proviral
opies. Similar findings have been observed after vaccinia
irus superinfection of monkeys infected with live attenu-
ted virus but not exposed to any challenge virus (Dittmer
t al., 1997). Based on a comparison of the data on the
roliferative responses observed in naive monkeys with
hose derived from vaccinated and control infected mon-
eys before the TT boosters, it seems that the failure to
etect proliferative responses is not dependent on the SIV
nfection per se.
In conclusion, our results demonstrate that vaccina-
ion with genotypically stable live attenuated virus can
licit a strong protection that seems to be independent
rom a cellular resistance to superinfection.
MATERIALS AND METHODS
nimals
Adult cynomolgus monkeys (Macaca fascicularis)
sed for this study were housed in single cages within
evel 3 biosafety facilities according to the European
uidelines for nonhuman primate care (EEC, Directive
o. 86-609, November 24, 1986). As a part of a routine
rocedure, all monkeys were vaccinated against tetanus
ccinated (7, 09, 33, and 46133) and Control (P2, 2V, and A91)
nge with Monkey-Derived SIVmac32H/spl
46133 P2 2V A91
VC VL VC VL VC VL VC VL
.2 2 ,1 2 2 2 2 2 2
. 2 N.D. 1 N.D. 1 N.D. 1 N.D.
C8) 2 2.4 (C8) 1 364 (SIV) 1 557 (SIV) 1 623 (SIV)
. 2 N.D. 1 N.D. 1 N.D. 1 N.D.
2 3 1 682 1 358 1 280.7
.2 2 58.7 1 10 1 214 1 113.4
2 ,1 1 89.3 1 158 1 81.44
2 ,1 1 245 1 321 1 103.80
2 ,1 1 68.8 1 144.1 1 65.00
MX174 human cell line.
etermined by semiquantitative PCR analysis as described in Materials
n of the nef gene. Characters in parentheses indicate the genotype of
performed on DNA extracted from PBMCs of monkeys by using RSAABLE 2
C8-Va
Challe
33
VL
8
N.D
,1 (
N.D
5
1
,1
,1
,1
ith CE
), as d
p regio
nalysis40 IU; Anatetal, Sclavo, Siena, Italy) at least 4.0 years
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297IMMUNE STIMULATION DOES NOT REACTIVATE ATTENUATED SIVefore SIV inoculation. Animals were clinically examined,
nd weight and rectal temperature measurements were
ade while they were under ketamine hydrochloride
nesthesia (10 mg/kg). Blood samples for hematological
nalysis and immunological and virological assays were
btained the morning before food administration.
chedule of treatment and doses of viruses
The SIVmac251, 32H, C8 (C8) cell-free virus, carrying a
2-bp deletion in the nef gene (obtained from M. Cranage
hrough MRC AIDS Reagent Project, Potters Bar, UK),
as grown in the human C8166 cell line and used to
ntravenously infect (5 3 104 TCID50) four adult male
onkeys serologically tested negative for SIV and STLV.
At 40 weeks p.i. with the C8 virus, the four infected
onkeys, along with four naive monkeys, were intrave-
FIG. 3. Percentage of CD41 cells in peripheral blood of the C8-vacc
) at the time of and after inoculation with SIVmac32H, spl.ously challenged with 50 MID50 of SIVmac251, BK28 iSIVmac, BK28) molecular clone grown in monkey PBMCs
provided by A. M. Aubertine, Institute National de la
ante` et de la Recherche´ Medical, Strasbourg, France).
One hundred three weeks after the first challenge with
he SIVmac, BK28, the four C8-infected monkeys, along with
hree naive monkeys, were intravenously challenged
ith 50 MID50 of monkey-derived SIVmac32H, spl. The
IVmac32H, spl challenge virus stock was prepared from a
pleen homogenate of a rhesus monkey inoculated with
IVmac251, 32H (Almond et al., 1994) and titrated in vitro in
uman T cells and in vivo in rhesus monkeys (Lu¨ke et al.,
996; Stahl-Hennig et al., 1996b) (provided by G.
unsman, Deutsches Primate Center, Goettingen, Ger-
any). In this study, the four cynomolgus monkeys inoc-
lated with the C8 virus are referred to as C8-infected or
8-vaccinated monkeys, whereas the naive monkeys
(7, 09, 33, and 46133; A) and naive infected monkeys (P2, 2V, and A91;inatednoculated with the SIVmac32H, spl are controls.
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298 SERNICOLA ET AL.ymphocyte subset determinations
Citrated whole blood was used for staining with two-
olor analysis using the following combinations of mono-
lonal antibodies: anti-CD20-PE and anti-CD2-FITC
clone L26 and clone MT910; DAKO, Glostrup, Denmark)
nd anti-CD8-PerCP (Leu-2a; Becton Dickinson Immuno-
ytometry System, San Jose, CA) combined with anti-
D4-PE (clone MT310; DAKO). Briefly, 100 ml of citrated
hole blood was incubated for 30 min at 4°C with mono-
lonal antibodies (10 ml each), washed twice with PBS
upplemented with 2.5% FCS, resuspended, and fixed in
BS (pH 7.4) containing 1% (w/v) paraformaldehyde. Ten
housand lymphocytes in each sample were analyzed by
ytofluorimetry (FACScan; Becton Dickinson Immunocy-
ometry System). Isotype-matched murine immunoglobu-
ins conjugated with the different fluorochromes were
sed as controls.
etection of anti-SIV antibodies and p27gag antigen in
lasma
Because there is a high sequence homology between
IV-2 and SIV, antibody titers to SIV were determined by
nd point dilution using an HIV-2 ELISA assay (Elavia
c-Ab-Ak II kit; Diagnostic Pasteur, Paris, France). Sam-
les that showed an optical density (OD) of .0.200 at
:100 dilution (log10 5 2) were scored as positive. SIV
FIG. 4. In vitro proliferative responses to TT (bars) and anti-tetanus Ig
onkeys (P2, 2V, and A91; B) are represented. The effects of TT stimul
hown. Arrows indicate the time at which TT treatment was given.27gag protein measurement was made in untreated tlasma by using an antigen capture ELISA assay (SIV
ore Antigen Assay, Coulter Immunology, Hialeah, FL)
ith limits of detection of 50 pg/ml.
irus isolation and in vitro infection of monkey
BMCs
For virus isolation, Ficoll–Paque (Pharmacia Bioteck
B, Uppsala, Sweden)-purified monkey PBMCs (4 3 106)
ere cocultured with 1 3 106 human CEMX174 cells
Salter et al., 1985) (obtained from AIDS Research and
eference Reagent Program, Division of AIDS, NIAID,
IH) in a 25-cm2 tissue culture flask. The cells, reseeded
very 3–4 days at 3 3 105 cells/ml, were maintained in
ulture for 30–40 days in RPMI 1640 containing 10% FCS
nd antibiotics. Samples were scored for syncytia forma-
ion, and clarified supernatants were monitored twice a
eek for the presence of p27gag antigen. Samples found
eactive to this assay at least twice were scored as
ositive.
For the in vitro infection, the virus stock was prepared
rom the supernatant of CEMX174 cells infected with
IVmac32H, spl. After infection, the cultures were monitored
or the presence of the reverse transcriptase activity (RT)
s described previously (Rossi et al., 1988). Cell-free
upernatants, showing the highest RT activity, were har-
ested on day 11 and titrated on uninfected C8166 (ob-
ls (lines) in C8-vaccinated (7, 09, 33, and 46133; A) and infected control
n viral load of C8-vaccinated (C) and infected control (D) monkeys areG leve
ation oained from AIDS Reagent Project, Programme EVA, Pot-
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299IMMUNE STIMULATION DOES NOT REACTIVATE ATTENUATED SIVers Bar, UK) on 96-well plates by 1:4 end point dilutions.
irus stock was stored in aliquots at 2152°C. The infec-
ious dose of the virus stock (2.2 3 106 TCID50/ml) was
xpressed as 50% tissue culture infectious dose (TCID50/
l) according to the method of Reed and Muench (1938).
or the in vitro infection, PBMCs (6.4 3 106) from C8-
accinated monkeys that were protected after the first
hallenge along with those from two naive monkeys
ere resuspended in 2.2 ml of the CEMX174-derived
tock of SIVmac32H, spl (multiplicity of infection, 1 TCID50/
ell) or with 2.2 ml of a mock supernatant from uninfected
EMX174 in the presence of PHA (0.1 mg/ml v/v) and
ncubated overnight at 37°C in 5% CO2. The cells were
ashed five times with PBS, and after the last wash,
larified supernatants were used to determine the base-
ine level of p27gag protein (time 0). The cells were finally
lated at 1 3 106 cells/ml in a 6-well tissue culture plate
n RPMI complemented with 15% FCS, antibiotics, and
L-2 (70 U/ml) (rhIL-2; Pepro Tech, Rocky Hill, NJ) and
inally incubated at 37°C in 5% CO2. At 3, 6, 10, and 13
ays after infection the cells were counted and reseeded
t 1 3 106 cells/ml in the presence of complete medium,
nd virus production was monitored by determining the
27gag antigen release in the clarified supernatants. DNA
xtracted from cell pellets (1 3 106) was analyzed by
CR to detect and to discriminate the SIV genomes, as
escribed below.
uantification of the SIV proviral copies, differential
CR, and nucleic acid sequencing
DNA was extracted from the whole blood by using a
ommercially available kit (QIAamp Blood Kit, QIAGEN
mbH, and QIAGEN Inc., Hilden, Germany). To verify the
uality of the DNA to be amplified, primers (PCO3, PCO4)
pecific for a 110-bp sequence of the human b-globin gene
ere used (Saiki et al., 1985). To determine the relative
umber of SIV proviral copies present in the experimental
amples, a semiquantitative DNA PCR was performed.
riefly, 1 mg of DNA was used to amplify a 496-bp region of
he gag gene of SIVmac251 (SG1096Ngag, SG1592CgagD;
indly provided by P. Kitchin, AIDS Reagent Project, Pro-
ramme EVA, Potters Bar, UK) in 100 ml of reaction mixture
or a total of 35 cycles, as described previously (Titti et al.,
996). To quantify the viral copy number, an external refer-
nce standard curve was prepared for each PCR experi-
ent by using the pCMRII-Dgag plasmid containing a
00-bp deletion (396 bp). The amplified products were
uantified by densitometric analysis (Ultrascan LX En-
ancer Laser Densitometer; LKB, Bromma, Sweden). The
elationship between OD values and the number of SIV-
gag molecules was analyzed by linear regression analy-
is (Statgraphics, Manugistics Inc., Cambridge, MA). In this
et of experiments, OD values were linearly related up to
.000 SIV-Dgag molecules (correlation coefficient 5
.954 6 0.026). The number of SIV proviral copies/mg of wNA was obtained by interpolating the OD values of mon-
ey samples with the reference curve. The lower limit of
etection was 1 SIV proviral copy/mg of DNA, but samples
ontaining 10 SIV proviral copies were invariably positive.
To distinguish between C8 and SIVmac32H, spl provi-
uses, a nested PCR assay was performed. For each
eaction, 1 mg of DNA was added to a PCR mixture
ontaining primers (LS4-nef, LS6-nef, 8982–9968) ampli-
ying a 986-bp region of the nef gene. The PCR mixture
total volume of 100 ml) contained 10 mM Tris–HCl, pH
.3, 50 mM Tris–HCl, 1.5 mM MgCl2, 0.001% (w/v) gelatin,
00 mM comcentration of each dNTP, and 400 ng of each
rimer. After an initial denaturation step at 95°C for 4
in, the samples were subjected to 35 cycles each of
.30 min at 95°C, 1.30 min at 55°C, and 2 min at 72°C
Thermal Cycler 9600; Perkin–Elmer Corporation, Nor-
alk, CT). Ten microliters of the product of the first round
f PCR were then added to a fresh mixture containing
rimers amplifying an inner region of the nef gene (LS1-
ef, LS2-nef, 9335–9691, 356 bp). After an initial denatur-
tion step of 4 min at 95°C, samples were subjected to
0 cycles each of 30 s at 95°C, 30 s at 55°C, and 1 min
t 72°C, followed by a final extension step of 10 min at
2°C. The final product (356 bp) was digested with the
saI restriction enzyme according to established proce-
ures (Rose et al., 1995), resolved by electrophoresis on
.5% agarose gel, and transferred onto a filter. Hybridiza-
ion was performed at 42°C with a 32P-labeled oligonu-
leotide probe (LS3-nef, 9587–9606). After washing, the
ilters were exposed to x-ray film for 12–18 h. This anal-
sis allows one to distinguish between undigested nef
roduct (356 bp) of C8 and the digested nef products (172
nd 184 bp) of the SIVmac32H, spl.
DNA extracted from PBMCs was amplified by using
rimers specific for the nef region (LS1–LS2, 356 bp). The
mplified products were separated onto a 2% agarose gel
nd eluted by using the QIAquick gel extraction kit
QIAGEN Gmbh and QIAGEN Inc.). Purified fragments were
enatured and sequenced by using Sequenase kit (Version
.0 USB; Amersham, Life Science, Cleveland, OH).
etanus toxoid vaccination, in vitro proliferative assay,
nd detection of anti-tetanus IgG
At 13 and 16 weeks after the second challenge, C8-
accinated and control monkeys were boosted intramus-
ularly with TT (40 IU/dose; Anatetal). To determine the
roliferative response time after vaccination with TT in
he absence of booster doses of antigen, a group of 23
aive monkeys was also included. In addition, four of
hese monkeys received two intramuscular booster
oses of TT at 3-week interval. To evaluate the prolifer-
tive responses to TT, Ficoll-purified PBMCs (2 3 105/
ell) were placed in flat-bottom 96-well microtiter culture
late in a final volume of 200 ml of RPMI complemented
ith 10% FCS along with (A) no stimulation, (B) PHA 2
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300 SERNICOLA ET AL.g/ml (v/v), or (C) TT 5 mg/ml (v/v) (Connaught, Ontario,
anada). Three replicate cultures were performed for
ach stimulation and incubated at 37°C in 5% CO2 for 5
ays. There was no change of the culture medium during
he incubation period. Cultures were then pulsed with 0.5
Ci/well of [3H]thymidine (specific activity, 25 Ci/mmol;
mersham Life Science, Buckingamshire) 5 days after
ntigenic stimulation, harvested 18 h later onto filter
aper using a 96-well harvester (Tomtec, Orange, CT),
nd washed three times with distilled water under pres-
ure. The filters were then dried, the scintillation fluid
as added, and the radioactivity was measured with a
etaplate (Betaplate 1205; Wallac, Turku, Finland). The
.I. was calculated by dividing the mean cpm values of
timulated samples by the mean cpm values of non-
timulated controls. An S.I. of .2 was scored as positive.
To evaluate the level of anti-tetanus IgG in the plasma
f monkeys either before or after the TT boosters, a
ommercial ELISA kit for human samples that cross-
eacts with monkey IgG was used (Tetanus IgG ELISA;
erion Institut, Wurzburg, Germany).
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